Carolyne C.
- Country
- France
- Department
- Service de thérapie cellulaire et d’hématologie clinique
Research Overview
- Phase 2 Study of Belantamab Mafodotin and Mezigdomide in Patients with Relapsed/Refractory Multiple Myeloma Following BCMA-Targeting CAR-T or Bispecific Antibody Therapy
- Phase II Evaluation of Ibrutinib and Rituximab in Treatment-Naïve CD20-Positive Marginal Zone B-Cell Lymphoma Patients Requiring Systemic Therapy
- Evaluation of Dexamethasone as Initial Therapy in Advanced Relapsed/Refractory Multiple Myeloma: A Randomized, Open-Label, Non-Inferiority Trial
Data & Insights
Has run more than one trial at 17 of 77 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the treatment of multiple myeloma, focusing on innovative therapeutic approaches in hematologic malignancies.
- Blood Cancer Management
- Novel Treatment Combinations
- Plasma Cell Disorders
Their research interests encompass advanced therapeutic strategies for newly diagnosed multiple myeloma patients.
Immunotherapy Research
The investigator explores targeted immunotherapy approaches in blood cancer treatment, with particular attention to innovative therapeutic combinations.
- Targeted Therapy Development
- Immune System Modulation
- Combination Therapy Strategies
Their work includes evaluation of novel immunotherapeutic agents in hematologic malignancies.
Treatment Optimization
The investigator focuses on therapeutic optimization in blood cancer treatment, including consolidation and maintenance therapy approaches.
- Treatment Response Assessment
- Long-term Disease Management
- Therapeutic Sequencing
Their expertise includes evaluation of treatment efficacy in various stages of multiple myeloma therapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.